GSK-269984A is found to cause a concentration-dependent rightward shift of the PGE2 dose-response curve and Schild analysis displays that GSK-269984A is a competitive antagonist with pA2 8.1±0.3 and slope 1.0[1].

GSK-269984A(10 mg/kg,p.o.) treatment, showing equivalent reversal of hypersensitivity to the standard(ED50: 2.6 mg/kg). GSK-269984A displays moderate blood clearance in the rat and dog and high clearance in the monkey which is reflected in the half-life for each species[1].